MedTrace Logo

Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.

NCT03213301 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2021-07-14

No results posted yet for this study

Summary

Aim of this study is to provide the "proof of concept" of efficacy and tolerability of lurbinectedin monotherapy in progressive malignant mesotheliomas.

Conditions

  • Malignant Pleural Mesothelioma, Advanced

Interventions

DRUG

Lurbinectedin

3.2 mg/m2 i.v. every 3 weeks

Sponsors & Collaborators

  • Swiss Cancer Institute

    lead OTHER

Principal Investigators

  • Yannis Metaxas, MD · Kantonsspital Graubünden, Chur

  • Roger von Moos, Prof · Kantonsspital Graubünden, Chur

  • Miklos Pless, MD · Kantonsspital Winterthur KSW

  • Federica Grosso, MD · SS. Antonio e C. Arrigo Hospital Alessandria (Italy)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-28
Primary Completion
2021-06-11
Completion
2021-06-11

Countries

  • Italy
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03213301 on ClinicalTrials.gov